
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech has demonstrated strong growth in its surgical soft tissue repair products, with a year-over-year increase of 24% in sales, contributing significantly to overall revenue. The company's recent contract with Vizient, the largest group purchasing organization in the U.S., is expected to enhance access to its products and drive future topline growth, alongside improvements in operational efficiency. Furthermore, the continued expansion of its product portfolio and enhancements in its sales and distribution network position Sanara MedTech for sustainable revenue growth and improved profitability in the coming years.
Bears say
Sanara MedTech reported net revenue of $26.3 million, which reflects a 21.5% year-over-year growth, yet this figure fell short of the projected $26.7 million. Key risks influencing a negative outlook include the potential for lower-than-expected revenue growth, challenges in attracting new customers, difficulties in launching new products or services, and risks related to potential dilution. Additionally, the company has seen a reduction in its enterprise value to revenue multiple from 4.3x to 3.0x as telehealth has been removed from its business model, contributing to concerns about its future growth trajectory.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares